Connection
Jill Johnson to Humans
This is a "connection" page, showing publications Jill Johnson has written about Humans.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.090 |
|
|
|
-
King J, McAdam-Marx C, McCaleb R, Davis D, Bemberg GB, Johnson JT. Cost and Utilization Outcomes After Exclusion of Dipeptidyl Peptidase-4 Inhibitors and Other Diabetes Drug Category Changes in a Self-Funded, State Employee Managed Care Plan. J Manag Care Spec Pharm. 2019 Jun; 25(6):646-651.
Score: 0.028
-
Dayer LE, Hutchins LF, Johnson JT. Treatment of metastatic melanoma with pazopanib: A report of five patient cases. J Oncol Pharm Pract. 2015 Jun; 21(3):224-31.
Score: 0.020
-
Neill KK, Johnson JT. An advanced pharmacy practice experience in application of evidence-based policy. Am J Pharm Educ. 2012 Sep 10; 76(7):133.
Score: 0.018
-
Johnson JT, Neill KK, Davis DA. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan. J Manag Care Pharm. 2011 Apr; 17(3):200-12.
Score: 0.016
-
Shewale AR, Johnson JT, Li C, Nelsen D, Martin BC. Net Clinical Benefits of Guidelines and Decision Tool Recommendations for Oral Anticoagulant Use among Patients with Atrial Fibrillation. J Stroke Cerebrovasc Dis. 2015 Dec; 24(12):2845-53.
Score: 0.005
-
West DS, Johnson JT, Hong SH. A 30-month evaluation of the effects on the cost and utilization of proton pump inhibitors from adding omeprazole OTC to drug benefit coverage in a state employee health plan. J Manag Care Pharm. 2006 Jan-Feb; 12(1):25-32.
Score: 0.003